期刊文献+

疫苗生产企业GMP现场检查中一些不足之处的商榷 被引量:3

The Discussion of Insufficiencies in GMP Spot Inspection at Vaccine Manufacturers
下载PDF
导出
摘要 就疫苗生产企业GMP检查时遇到的一些问题,如:在检查过程中过于注重硬件而相对轻视软件建设和执行的检查;关注产品的成品质量而对生产过程的检查相对较松;对疫苗的固有特性、生物安全、原辅材料的质量检查不严;检查员欠缺对生物制品生产和检定的专业知识等,与同行讨论商榷。 Some insufficiencies of vaccine manufacturers which were inspected during GMP spot inspection will be introduced and discussed in this essay. For instance, manufacturers pay more attention on hardware examination and comparatively less on software establishment and related performed inspection. Qualities of the final products are highly concerned whereas the inspections of production process are undemanding. Moreover, vaccine intrinsic property, biosafety issues and the qualities of both raw material and accessories are not under the satisfied strict controls. Beside of these, the inspectors lack of related background of biologic product processing and inspection is also a serious problem which will be discussed in this essay.
作者 董关木
出处 《中国药事》 CAS 2008年第11期1022-1023,1030,共3页 Chinese Pharmaceutical Affairs
关键词 疫苗 GMP检查 产品质量 vaccine GMP inspection products quality
  • 相关文献

参考文献9

  • 1十年磨剑.浅议《药品生产质量管理规范》(GMP)的实施及功绩[EB/OL][2008-09-01].http://221.122.47.241/ccd/main?fid=open&fun=show_news&from=view&nid=4677.
  • 2药品生产质量管理规范[S].国家药品监督管理局令第9号.1998.
  • 3Good manufacturing practices for biological products[S].WHO Technical Report Series,1992,822:20.
  • 4Requirements for the use of animal cells as in vitro substrates for the production of biologicals. In: WHO Expert Committee on Biological Standardization. Fortyseventh report [S], Geneva, World Health Organization, 1998, Annex 1 (WHO Technical Report Series, No. 878).
  • 5Specifications: Test Procedures and Acceptance Criteria for Biotechnological/ Biological Products [EB/OL]. [2008-09- 01] .http: //www. emea. europa. cu/pdfs/human/ich/ 036596cn. pdf.
  • 6Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs, WHO EMJ. WHO Expert Committee on Biological Standardization, Geneva 2007, Fifty-sixth Report, TRS 941: 83.
  • 7WHO Guidelines on Transmissible SFongiform Encephalopathies in relation to Biological and Pharmaceutical Products [EB/ OL]. [2008-09-09] . http: //www. who. int/biologicals.
  • 8病源微生物实验室生物安今管理条例[S].国务院令第424号.2004.
  • 9WHO Guidelines on Transmissible Spongiform Encephalopathies in relation to Biological and Pharmaceutical Products [ EB/ OL]. [2008-09-09] .http: //www. who. int/biologicals.

共引文献4

同被引文献19

  • 1龚时薇,张亮,黄杰敏,詹学锋,姜卫,王成江.药品安全与风险管理[J].中国药房,2007,18(22):1687-1690. 被引量:45
  • 2药品召回管理办法[S].国家食品药品监督管理局令第29号.2007.
  • 3国家药典委员会.提高国家药品标准行动计划[EB/OL].(2005-10-10)[2008-12-20].http://www.cap.org.cn.
  • 4药品不良反应报告和监测管理办法[J].国家食品药品监督管理局令第7号,2004.
  • 5国家食品药品监督管理局.关于推动药品生产企业实施药品质量受权人制度的通知[z].国食药监安[2009]121号,2009.
  • 6突发事件应对法[s].中华人民共和国主席令第69号,2007.
  • 7突发公共卫生事件应急条例[s].国务院令第376号,2003.
  • 8药品生产监督管理办法[S].国家食品药品监督管理局令第14号,2004.
  • 9国务院办公厅.关于进一步加强药品安全监管工作的通知[z].国办发[2007]18号,2007.
  • 10杜蕾.美国FDA的药品风险管理及监督管理工作机制[J].上海食品药品监管情报研究,2007(5):5-8. 被引量:12

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部